News

Diet, Not Exercise Improves Diabetes Control in the Newly Diagnosed

View on the News

Questions Remain on the Value of Exercise

Previous clinical trials have shown that increased physical activity, including brisk walking, significantly improves glycemic control among patients with preexisting diabetes. A combination of aerobic exercise and resistance training, in particular, is more beneficial than is aerobic exercise or resistance training alone.

The Early ACTID trial did not include a group assigned to physical activity only and, therefore, the results do not necessarily mean that an increase in physical activity is ineffective for diabetes management. It is possible that modification of two complex behaviors at the same time is no more effective than a change in one, that is, the need for effort in both aspects of life diminishes positive dietary changes by patients in the diet plus activity group.

Another question is whether the improvement in outcomes is clinically significant. At 6 months, diet alone improved hemoglobin A1c by 0.28% vs. 0.33% with diet and exercise, from a mean baseline value of 6.7%. The differences are slight but clinically meaningful; a decrease in HbA1c of 1% (about 11 mmol/mol) can reduce rates of major cardiovascular disease events by 12% to 16% and microvascular complications by 37%.

Moreover, diet and physical activity can exert long-term health benefits beyond improvement of metabolic markers. The reduction in HbA1c through diet and exercise in the Early ACTID study was comparable to the effect of sitagliptin and metformin among patients who had received no previous treatment for type 2 diabetes.

The long-term effects and cost-effectiveness of lifestyle-modification interventions need to be assessed. There is little doubt that improved nutrition and physical activity are beneficial for individuals with or without diabetes, and research into the most effective way to deliver these benefits, including individual behavioral changes and creation of a supportive food and social environment, deserves high priority.

Dr. Frank B Hu is with the department of nutrition and the department of epidemiology, Harvard School of Public Health, Boston. Dr. Hu disclosed that he has received grants from Merck and the California Walnut Commission, and has been paid for lectures from Nutrition Impact, Unilever, and the Institute of Food Technologists. His comments were taken from an editorial accompanying the study (Lancet 2011 [doi:10.1016/SO140-6736(11)60692-1]).


 

FROM THE ANNUAL SCIENTIFIC SESSIONS OF THE AMERICAN DIABETES ASSOCIATION

The attempt to modify two behaviors simultaneously might have diluted the effect of both. "Qualitative interview results suggest that people use a trade-off system in which they reward themselves for additional exercise with increased food intake," Dr. Andrews and his associates commented.

"I found it a little surprising that there was no additional benefit of exercise, but perhaps it’s true that people didn’t adhere as well to the diet, or perhaps the diet is just so powerful in the beginning that exercise doesn’t add that much," observed Dr. Sue Kirkman, senior vice president of medical affairs and community information for the ADA.

Dr. Andrews added, "We’re not saying exercise isn’t useful. We’re saying exercise didn’t improve the parameters that we measured. There’s a lot of clear evidence that individuals who exercise have a reduced cancer rate, reduced mortality, and get other benefits from exercising like well-being. ... In this context if we want to get HbA1c better the first thing to do is concentrate on diet. We’re not saying don’t do exercise," he said in an interview.

"The Early ACTID trial shows clearly that intensive dietary support soon after the diagnosis of type 2 diabetes is beneficial. ... Our findings support the redesign of diabetes services to increase dietary management at an early stage. Because the intensive diet intervention was designed to be delivered by practice nurses with dietitian support, this approach could be translated into community-based services," they concluded.

The study was funded by Diabetes UK and the UK Department of Health. Two of the researchers reported financial relationships with companies including Bristol-Myers Squibb, GlaxoSmithKline, Medtronic, Novartis, Novo Nordisk, Sanofi-Aventis, and Eli Lilly.

Pages

Recommended Reading

Normal Folate Levels Associated With Depression in Diabetes
MDedge Internal Medicine
Statin Cuts Recurrent Stroke Risk Similarly in Diabetic, Nondiabetic Patients
MDedge Internal Medicine
Liraglutide Risks Revisited in Company Letter to Clinicians
MDedge Internal Medicine
FDA Warns of Possible Bladder Cancer Risk With Diabetes Drug
MDedge Internal Medicine
FDA Issues Draft Guidance on Artificial Pancreas Component
MDedge Internal Medicine
Diabetes Risk Rises as Statin Dose Increases
MDedge Internal Medicine
Some DMARDs for RA or Psoriasis Cut Diabetes Risk
MDedge Internal Medicine
Fries Fatten Widening Waistlines
MDedge Internal Medicine
ACIP Considers Hepatitis B Vaccine for Adults with Diabetes
MDedge Internal Medicine
Anastomotic Leak After Colectomy: Preop Hyperglycemia Ups Death Risk
MDedge Internal Medicine